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Abstract
Background: Lung cancer still remains one of the most commonly occurring solid tumors and even in
stage Ia, surgery fails in 30% of patients who develop distant metastases. It is hypothesized that these must
have developed from occult circulating tumor cells present at the time of surgery, or before. The aim of
the present study was to detect such cells in the peripheral blood and to monitor these cells following
surgery.
Methods: 30 patients treated for lung cancer with surgery were monitored for circulating epithelial cells
(CEC) by taking peripheral blood samples before, 2 weeks and 5 months after surgery and/or radiotherapy
(RT) chemotherapy (CT) or combined RT/CT using magnetic bead enrichment and laser scanning
cytometry (MAINTRAC®) for quantification of these cells.
Results: In 86% of the patients CEC were detected before surgery and in 100% at 2 weeks and 5 months
after surgery. In the control group, which consisted of 100 normal donors without cancer, 97 % were
negative for CEC. A significantly higher number of CEC was found preoperatively in patients with
squamous cell carcinoma than in those with adenocarcinoma. In correlation to the extent of parenchymal
manipulation 2 weeks after surgery, an increase in numbers of CEC was observed with limited resections
(18/21) whereas pneumonectomy led to a decrease (5/8) of CEC, 2 weeks after surgery. The third analysis
done 5 months after surgery identified 3 groups of patients. In the group of 5 patients who received neo-
or adjuvant chemo/radiotherapy there was evidence that monitoring of CEC can evaluate the effects of
therapy. Another group of 7 patients who underwent surgery only showed a decrease of CEC and no signs
of relapse. A third group of 11 patients who had surgery only, showed an increase of CEC (4 with an initial
decrease after surgery and 7 with continuous increase). In the group with a continuous increase during the
following 24 months, 2 early relapses in patients with stage Ia adenocarcinoma were observed. The
increase of CEC preceded clinical detection by six months.
Conclusion: We consider, therefore, that patients with adenocarcinoma and a continuous increase of
CEC after complete resection for lung cancer are at an increased risk of early relapse.
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Background
Lung cancer still remains the most frequent solid tumour
in men and represents the leading cause of death in
women since the 1980s in the USA [1]. Due to a steady
increase in cigarette smoking, even in Europe and Ger-
many, lung cancer has become three times more common
in women during the last 20 years [2].
Despite good progress in diagnosis, operative and multi-
modality treatment of patients with lung cancer the prog-
nosis has remained persistently bad during the last 50
years, with 5 years survival rates of 9% for all patients [3].
The therapeutic dilemma becomes evident if results from
stage Ia lung cancers are examined. If patients undergo a
complete resection, the therapy of choice, then the 5 year
survival is 70%. But treatment has failed for the 30% of
patients who develop distant metastases in the two years
following surgery [4]. The metastases in these patients
must have developed from occult circulating tumor cells
present at the time of their original surgery, or before,
leading to an underestimation of the true tumor stage.
Pantel et al [5] detected epithelial cells in 20–25 % of
biopsies taken intra-operatively from bone marrow after
resection of lung cancers. Nevertheless, even today the
role of cytokeratin positive cells in bone marrow remains
unclear. They may have come from the tumor at an early
stage, or seeded into the circulation during surgery. lt is
also not clear whether these cells have proliferative activ-
ity or are so-called dormant cells [6].
Using a method for rapid determination of circulating
epithelial cells (CEC) in peripheral blood [7], which
allows monitoring of these cells under therapy, we dem-
onstrate that a single examination is not sufficient to
determine outcome. However, it is necessary to monitor
the behavior of these cells over time to be able to predict
tumor recurrence.
Methods and methods
Anti-coagulated peripheral blood samples were drawn
after informed consent from a control group of 100 nor-
mal subjects aged between 17 and 73 years and from 30
successive patients before, and two weeks after, surgery for
lung cancer. A third sample was obtained 3 to 5 months
postoperatively when the patients were seen for follow-
up. In all patients routine controls were continued up to
27 months or death with a median follow-up of 22
months.
Seven patients were excluded. In one patient lung cancer
was not confirmed after histological examination and in
another patient lung cancer was combined with advanced
sarcoidosis. In 5 patients one or two samples were missing
therefore these cases were omitted as well, despite there
being no further discrepancy. Of the remaining 23
patients, for which all data and follow-up were complete,
20 were male (mean age 64 years, range 55 – 74 years)
and 3 were female (mean age 53 years, range 40 – 74
years) with a balanced proportion of early to advanced
stages of lung cancer (12:11). Staging was performed by
chest x-ray, endobrochial bronchoscopy, computerized
tomography (CT), bone scan, operative lymph node dis-
section and size of tumor-free margin. Further informa-
tion about surgery, histological type of tumor stage and
the number of CEC is depicted in table 1.
Cell preparation
Red blood cells from 10 ml samples of blood were lysed,
the white blood cells spun down and epithelial cells were
enriched using micro-beads from Miltenyi (Bergisch
Gladbach, Germany) [7] or the method by Labsoft Diag-
nostics (Halle, Germany) [8]. Both methods yielded com-
parable results. The same method was always used in
follow-up samples from the same patient. Cells were
stained with FITC conjugated mouse anti-human epithe-
lial antibody (HEA, Milteny, Bergisch Gladbach, Ger-
many), reacted either with HEA-micro-beads Miltenyi
(Bergisch Gladbach, Germany) or Cell Select-micro-beads
(Labsoft Diagnostics Halle, Germany) and then either
separated over the columns provided by the Miltenyi
company according to their description or the vials con-
taining the cells were applied to magnets provided by the
Labsoft company. Negative cells not bound in the col-
umns were washed out, the columns removed from the
magnet and the retained cells eluted. In the Labsoft
method cells not attached to the vial wall were sucked off,
the vials removed from the magnet and the cells retained
in the vials were then flushed off the wall and studied.
Analysis
For measurements the cells were applied to adhesion
slides (Menzel, Gläser, Germany) and measurements
started when the cells had settled using a Laser Scanning
Cytometer (LSC®  Compucyte Corporation, Cambridge,
MA, USA). The cells could easily and unequivocally be
contoured using forward scatter as a threshold parameter.
Background fluorescence was determined dynamically to
calculate both peak and integral fluorescence on a per-cell
basis making the fluorescent calculation equivalent for all
cells. The green fluorescence was displayed as scattergrams
and histograms.
The LSC® enables the user to relocate cells contained
within the positive population for visual examination
through the microscope (Figure 1). In addition a CCD
camera attached to the microscope allowed taking photo-
and fluoromicrographs at the same time. More detailed
morphology could be determined in conventional pano-
ptic staining (Figure 1).World Journal of Surgical Oncology 2005, 3:18 http://www.wjso.com/content/3/1/18
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Results
Circulating epithelial cells (CEC) were detectable in blood
samples from 25/29 patients (86%) before surgery,
whereas 97% of normal controls were negative for these
cells. The number of CEC was calculated in relation to the
analyzed blood volume and not to white blood cells,
which vary considerably during the course of disease. For
26 patients histological evaluation was available and
Table 1: Data from 23 patients operated for lung cancer
CEC Levels
No age sex tumor 
histology
operation Pathologic 
stage
1st analysis 
pre op
2nd analysis 2 
weeks pop
3nd analysis 
5 month 
pop
Change therapy follow up
1 55 M squamous pneumonectomy III a 769.091 664.210 853.333 ⇒ neoadj. CT Ø R 24 months
2 62 M squamous pneumonectomy II b 0 474.375 5.722.667 Ø R 27 months
3 68 M squamous bilobectomy I b 5.396.667 2.222 65.000 Ø R 25 months
4 68 M squamous pneumonectomy III a 1.514.583 80.000 35.185 Ø R 25 months
5 67 M squamous pneumonectomy I b 292.592 292.592 1.312.000 Ø R 26 months
6 57 M squamous lobectomy I b 64.942 476.667 610.000 Ø R 26 months
7 68 M adeno pneumonectomy III a 1.000.000 110.000 96.429 ⇒ adj. RT T † 26 months
8 66 M squamous pneumonectomy I b 0 5.000 203.333 Ø R 25 months
9 56 M adeno lobectomy I a 224.118 615.556 1.656.000 R † 24 months
10 74 M squamous explorative III b 127.059 147.000 70.000 adj.CT T alive 25 
months
11 60 M adeno lobectomy I b 3.158 203.333 13.889 Ø R 22 months
12 61 M adeno lobectomy I b 28.500 6.667 46.667 Ø R 25 months
13 41 F adeno lobectomy I a 20.625 51.667 98.333 R † 11 months
14 67 M squamous pneumonectomy II b 16.667 9.259 93.333 Ø R 14 months
15 69 M adeno segmentectomy I b 6.667 25.000 100.000 Ø R 24 months
16 68 M adeno explorativ III b 71.667 140.000 263.571 adj. CT/RT T † 9 months
17 65 M adeno lobectomy I b 0 335.000 182.857 Ø R 13 months
18 71 M adeno lobectomy I b 22.941 17.778 1.605.185 Ø R 23 months
19 68 M adeno lobectomy III a 6.667 57.647 11.111 adj. RT Ø R 23 months
20 66 M adeno lobectomy I a 126.667 154.286 38.571 Ø R 22 months
21 57 M squamous pneumonectomy I b 473.333 1.031.250 503.333 Ø R 23 months
22 74 F squamous lobectomy II b 11.053 160.000 150.000 ⇒ Ø R 19 months
23 56 F adeno segmentectomy I b 5.000 2.670.370 576.190 Ø R 23 months
CT = Chemotherapy, RT = Radiotherapy, R = Recurrence, ∅ R = no Recurrence, T = Tumor, T † = died with tumor, adj. = adjuvant, neoadj. = 
neoadjuvant, Pop = Postoperatively, Adeno = Adenocarcinoma, Squamous = Squamous carcinoma
⇑
⇑
⇓
⇑
⇑
⇑
⇑
⇓
⇓
⇑
⇑
⇑
⇑
⇑
⇓
⇑
⇓
⇓
⇓
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revealed 15 cases of adenocarcinoma and 11 cases of
squamous cell carcinoma. The comparison of preopera-
tive numbers of CEC revealed higher values in patients
with squamous cell than in those with adenocarcinoma
and these values differed significantly (p = 0.046) (Figure
2). Neither tumor size nor positivity of lymph nodes cor-
related with the number of circulating tumor cells before
surgery. With regard to the extent of resection 1 pleurec-
tomy, 8 pneumonectomies, 1 bilobectomy, 12 lobecto-
mies, 4 segmental resections and 3 explorative
thoracotomies were performed. Lobectomy was more fre-
quent than pneumonectomy in patients with adenocarci-
noma (69% vs. 36%) and pneumonectomy more
frequent than lobectomy in those with squamous cell car-
cinoma (54% vs. 6%) (Figure 3).
Example of an analysis of a slide with epithelial antigen positive and negative cells: a) fluorescence intensity displayed as a dot  plot with all cells in region 1 and the positive cells gated in region 2 (green region) Figure 1
Example of an analysis of a slide with epithelial antigen positive and negative cells: a) fluorescence intensity displayed as a dot 
plot with all cells in region 1 and the positive cells gated in region 2 (green region). b) The scanning stage proceeds from one 
positive event to the next stopping at each position of a positive event and allowing the observer to control whether it repre-
sents a specific membrane stained cell as shown in figure 1c. c) Three typical cells shown with green fluorescence. In the lower 
panel the identical cell is shown in panoptic staining indicated by the arrow.World Journal of Surgical Oncology 2005, 3:18 http://www.wjso.com/content/3/1/18
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Fourteen days postoperatively, CEC were detected in all
patients including the 3 where no cells had been detecta-
ble before surgery. In cases with limited resection (3
exploratory thoracotomies, 4 segmental resections, 12
lobectomies, 1 bilobectomy) parenchymal manipulation
was more extensive. This resulted more frequently in an
increase (85.7%) than in a decrease (14.3%) in CEC,
whereas in cases of complete resection of the lung
(pneumonectomy) numbers of CEC decreased (62.5%)
more frequently than increased (37.5%) (Figure 4). We,
also, investigated CEC in one patient who had surgery for
pneumothorax and observed a comparable increase in
CEC as in the tumor patients but with a rapid re-decrease
already after another two weeks (Figure 5a).
A third analysis of CEC was performed between 3 and 5
months after surgery. In 23 (76%) of 30 consecutive
patients considered to have a resectable non small cell
lung cancer (NSCLC) complete data were available with a
median follow-up of 22 months (range 9 – 27 months)
(Table 1).
Five out of 23 patients underwent chemotherapy (CT) or
chemo/radiotherapy (CT/RT). These patients were consid-
ered separately from the 18 patients who had complete
curative resection of their tumors without adjuvant treat-
ment. Two patients underwent exploratory thoracotomy:
one with squamous cell carcinoma (patient 10) was
treated with adjuvant CT with a subsequent decrease in
CEC and is still alive 25 months after surgery. The other
patient with adenocarcinoma (patient 16) showed an
increase in CEC in spite of combined RT/CT and died 9
months later with tumor progression.
Three of the 21 patients with tumor resection received
additional treatment: 1 lobectomy patient with adenocar-
cinoma had N2 lymph node status (patient 19). This
patient with one level N2 status received adjuvant RT. He
subsequently showed a decrease in CEC and is alive, 23
months after surgery without signs of relapse. One patient
with squamous cell carcinoma (patient 1) received neoad-
juvant therapy and subsequently was treated with
pneumonectomy. He showed a slight increase in CEC but
is still alive without signs of relapse. Another patient with
adenocarcinoma (patient 7) underwent RT but with no
significant decrease in CEC and died 26 months later with
Number of preoperative circulating tumor cells in compari- son to histological classification Figure 2
Number of preoperative circulating tumor cells in compari-
son to histological classification.
Frequency of surgical interventions in comparison to histo- logical classification Figure 3
Frequency of surgical interventions in comparison to histo-
logical classification.
Changes in cell numbers (increase or decrease) following  surgical intervention Figure 4
Changes in cell numbers (increase or decrease) following 
surgical intervention.World Journal of Surgical Oncology 2005, 3:18 http://www.wjso.com/content/3/1/18
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tumor progression. Among these patients receiving
additional radio- and/or chemotherapy relapses occurred
only in those with adenocarcinoma and increasing CEC
numbers in spite of treatment.
Of the remaining 18 patients who had complete curative
resection of their tumors, 7 showed a decrease, and 11
showed an increase in CEC during the 3–5 months fol-
low-up after surgery.
Of the former 7 patients 6 had had cell numbers increas-
ing after surgery and subsequently decreasing during the
following months (patients 11, 17, 20, 21, 22, 23), 4 with
adeno- and 2 with squamous cell carcinoma and all but
one (patient 21) had lobectomy (Figure 5a). All are in
complete continuous remission. 1 patient (patient 4) with
squamous cell carcinoma had pneumectomy and contin-
uously decreasing cell numbers (Figure 5c) and he, too, is
in complete continuous remission.
Among the 11 patients with increasing CEC there were 4
with an initial decrease after surgery followed by a subse-
quent increase (Figure 5c). None has shown early relapse
so far. Seven had a continuous increase from pre-surgery
Trends of CEC numbers in individual patients after complete resection without further treatment Figure 5
Trends of CEC numbers in individual patients after complete resection without further treatment: a) patients with an increase 
in CEC 14 days after surgery and a subsequent decrease during the next five months (dotted lines: squamous cell cancer; solid 
lines: adenocarcinoma; fat line and squares: patient with benign lung disease pneumothorax) b) patients with an increase in CEC 
14 days after surgery and a subsequent further increase during the next five months (dotted lines: squamous cell cancer; solid 
lines: adenocarcinoma; fat lines: relapsed patients) c) patients with a decrease in CEC 14 days after surgery (dotted lines: squa-
mous cell cancer; solid lines: adenocarcinoma)World Journal of Surgical Oncology 2005, 3:18 http://www.wjso.com/content/3/1/18
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to 5 months after treatment (Figure 5b), 4 with squamous
cell carcinoma and 3 with adenocarcinoma. Two relapses
were observed amongst these patients during the subse-
quent 2 years of follow-up. Both, a male (56 years of age)
and a female (41 years of age), had adenocarcinoma stage
Ia. They had continuously increasing CEC and the
increase occurred six months before repeated clinical
examinations could verify disease relapse. Both received
chemotherapy after diagnosis of relapse but died despite
9 and 24 months after surgery with systemic spread of
their tumor.
In summary, amongst the patients with adjuvant treat-
ment after resection, as well as in curatively resected
patients, patients with adenocarcinoma and a continuous
increase in CEC during the course of their disease have a
significantly higher risk of early relapse than those with
decreasing cell numbers and than those with squamous
cell carcinoma, even if the latter show increasing numbers
of CEC.
In the relapsed patients not single values of circulating
tumor cells at different time points but only the increase
in cell numbers was a predictor of relapse.
Discussion
Analyzing circulating epithelial cells in peripheral blood
from patients with non small cell lung cancer, we were
able to detect live CEC in 86% of patients before surgery.
This represents a significantly higher number and fre-
quency than reported from other groups analyzing
micrometastases taken from bone marrow [9,10] but cell
numbers are in the same range as those reported by
Cristofanilli and coworkers [11]. This discrepancy may be
explained by several modifications of pre-analytical han-
dling: 1) In contrast to the former authors [9,10] we used
red blood cell lysis [7] for white blood cell preparation.
During ficoll-separation used for preparation of cells from
bone marrow aspirates we observed a loss of up to 90%
epithelial antigen positive cells and there is no reason why
circulating epithelial cells should have the same density
properties as mononuclear cells (Pachmann submitted for
publication]. 2) Micrometastatic cells can be hidden in
the fat lumps of the bone marrow aspirates and thus be
lost for analysis when preparing mononuclear cell suspen-
sions. 3) The portion of blood admixed to marrow aspi-
rates can vary between 10 and 90% resulting in a high
variability of the material used for analysis. Although the
method applied by us is also suitable for bone marrow
samples, we preferred analysis of peripheral blood
samples which are easy to obtain and can be drawn
repeatedly.
The number of CEC detected by us in lung cancer patients
is somewhat lower than the number reported recently by
Cristofanilli et al [11] in metastatic breast cancer patients.
In positive patients we found between 2000 and 6 × 106
epithelial cells calculating the number of cells in the circu-
lation assuming that a patient has about 5 liters of blood.
The values of 5 to 22000 cells per 7.5 ml blood reported
by Cristofanilli et al [11] would translate into 3000 to 13
× 106 cells in the circulation. The frequency of preopera-
tively CEC positive patients was comparable to that
reported by Racila et al [12] and Krag et al [13] who also
used a similar method for analyzing blood from breast
cancer patients.
We preferred detection of fluorescent antibody bound to
the surface of live epithelial antigen positive cells per-
formed by an automated Laser Scanning Cytometer LSC®
to PCR based methods. PCR methods are currently
regarded as the most sensitive procedures, but there is a
reported high frequency of false positives [14-16]. In addi-
tion, our procedure allowed subsequent separation and
even culturing of the isolated cells. Culturing will defi-
nitely allow determination whether the cells are dormant
or have the potency of differentiating into tumor cells.
It should be mentioned that we observed significantly
higher numbers of CEC preoperatively in patients with
squamous cell carcinoma than in those with adenocarci-
noma. This could be due to the former being more cen-
trally located (next to the great vessels) which might lead
to a higher dissemination than occurs in more peripher-
ally located tumors.
Two weeks after surgery all patients were positive for CEC,
but there was no correlation to stage, tumor size or lymph
node involvement. Unexpectedly we found a strong corre-
lation between postoperative increase and limited resec-
tions (segmental resections and lobectomies) and a
decrease of CEC after pneumonectomies. We can only
explain this observation by the extended parenchymal
manipulation involving the separation of parenchymal
bridges between lobes and late ligation of pulmonary ves-
sels during lobectomies or segmentectomies. In contrast,
pneumonectomies normally start with ligation of the ves-
sels and subsequent resection of the lung. Perhaps our
data confirm once more the importance of careful "No
touch" preparation during oncological resections [17].
However, during parenchymal resections also, normal
epithelial cells from the lung can be mobilized and
washed out entering the vessels. This may be true in the
cases where we observed a reduction of CEC during the
following six months of observation. Our attempts to dif-
ferentiate benign isolated epithelial cells from malignant
cells by their morphology failed, and molecular biological
techniques will need to be applied [18,19] to solve this
problem. But generally the premise is accepted, that dis-World Journal of Surgical Oncology 2005, 3:18 http://www.wjso.com/content/3/1/18
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seminated normal cells will die in a short time and only
the portion of cells that are malignant will have a chance
of survival for unknown periods of time. [18]. Monitoring
the CEC after five months would, therefore, be expected to
detect only surviving malignant epithelial cells. Once
again we found CEC in all patients.
Analysis of the increase or reduction of CEC in the 5
patients receiving neoadjuvant and/or adjuvant CT and
RT due to their nodal status indicated that this parameter
can possibly become a tool for monitoring the effective-
ness of therapeutic interventions, an effect that we are
actually investigating now in patients receiving CT for
lung cancer.
Of the 18 patients treated with complete curative resec-
tion all 7 patients of the group with decreasing numbers
of CEC were without signs of relapse up to 27 months
after surgery. In the group of 11 patients with increasing
numbers of CEC, 6 had squamous cell carcinomas and
none has relapsed during the observation time of 2 years
in accordance with published data [20]. In contrast, in the
group of adenocarcinomas 2/5 early relapses were
observed, both in patients with stage Ia with the increase
in CEC preceded overt clinical relapse by 6 months.
Conclusion
Thus, postoperative monitoring of CEC may become a
reliable prognostic predictor of relapse. The observation
that only 20% of the patients in the group at risk develop
early relapse confirmed by other studies [21] and that
patients with squamous cell carcinomas can have high
and over time even increasing numbers of CEC necessitate
additional analyses on the CEC to obtain more informa-
tion about their metastatic potential [22]. Such analyses
on enriched and cultured isolated CEC are now under way
in our laboratory.
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